Nonparametric statistical analysis

26 May 2020 - Many statistical methods start with a statistical assumption that the distribution of measured values can be summarised ...

Read more →

Modelling epidemics with compartmental models

27 May 2020 - During epidemics, there is a critical need to understand both the likely number of infections and their ...

Read more →

Prediction models - development, evaluation and clinical application

23 April 2020 - When national lipid guidelines first incorporated a model based on data from the Framingham Heart Study — ...

Read more →

Improving transparency in decision models: current issues and potential solutions

23 October 2019 - Decision-analytic models have become an essential tool used to inform health technology assessments. ...

Read more →

Model assisted designs for early phase clinical trials: simplicity meets superiority

30 October 2019 - Drug development enterprise is struggling because of prohibitively high costs and slow progress.  ...

Read more →

Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States

5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...

Read more →

Marginal effects—quantifying the effect of changes in risk factors in logistic regression models

8 March 2019 - Marginal effects can be used to express how the predicted probability of a binary outcome changes ...

Read more →

Choosing a time horizon in cost and cost-effectiveness analyses

21 February 2019 - When designing a comparative outcomes or a cost-effectiveness analysis, the time horizon defining the duration of time ...

Read more →

Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective

18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings.  ...

Read more →

Model structuring for economic evaluations of new health technologies

17 October 2018 - In countries such as Australia, the UK and Canada, decisions on whether to fund new health technologies ...

Read more →

Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?

21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions.  ...

Read more →

Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology

11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...

Read more →

Google is training machines to predict when a patient will die

19 June 2018 - The advances coming from the Medical Brain team give Google the chance to break into a brand ...

Read more →

Takeda pioneers NICE’s new service for economic model review

7 June 2018 - NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and ...

Read more →

ICER announces new program to make available draft executable economic models during drug assessment review process

30 March 2018 - Pilot program will allow more extensive evaluation of draft economic models used in ICER's reports. ...

Read more →